Related Experiment Video
Updated: Feb 27, 2026
11:27
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
17.2K
Cabozantinib use in renal cell carcinoma
A J Neuwelt1, S Mathur2, A T Johnson1
1University of Colorado School of Medicine, Division of Medical Oncology, Aurora, Colorado, USA.
Drugs of Today (Barcelona, Spain : 1998)
|June 27, 2017
Summary
Cabozantinib, a novel multikinase inhibitor, shows superiority over everolimus in treating advanced renal cell carcinoma (RCC). Its safety profile is comparable to other RCC treatments, making it a valuable option for patients.
Area of Science:
- Oncology
- Pharmacology
- Medical Science
Background:
- Metastatic renal cell carcinoma (RCC) has seen numerous drug approvals recently.
- Cabozantinib is a new multikinase inhibitor targeting VEGFR, Ret, and other kinases.
- It represents a significant addition to the therapeutic options for advanced RCC.
Purpose of the Study:
- To review the pharmacologic and safety profile of cabozantinib.
- To explore the preclinical and clinical activity of cabozantinib in RCC.
- To assess its efficacy in patients with progressive disease after prior antiangiogenic therapy.
Main Methods:
- Review of preclinical data and clinical trial results.
- Analysis of a phase III randomized study comparing cabozantinib to everolimus.
- Evaluation of safety and toxicity profiles.
Main Results:
- Cabozantinib demonstrated superiority over everolimus in a phase III study.
- The drug is active in both preclinical and clinical settings for RCC.
- Its toxicity profile is similar to other approved multikinase inhibitors.
Conclusions:
- Cabozantinib is an effective treatment option for patients with advanced RCC.
- It offers a favorable efficacy and safety profile for progressive disease.
- Further understanding of its role in RCC treatment is warranted.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
14.5K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
4.0K
Related Concept Videos
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
01:25Renal Drug Excretion: Tubular Reabsorption
974
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
974
01:06Renal Drug Clearance: Overview
897
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
897
01:11Renal Failure: Dose Adjustments
534
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
534
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K